|
 umerous preliminary clinical studies continue to show promise of the remarkable weight loss,
and other health benefits provided by the active KGM (Konjac glucomannan) compound found in both Tetrazene products. The below
clinical abstract summaries of KGM studies, serve to detail the protocols and results of these key studies for your reference and review.
- Patients report less hunger and greater satiety with glucomannan.
A study done in Italy utilizing glucomannan in conjunction with a reduced calorie program demonstrated better results
than diet alone including less hunger and greater satiety than those given a placebo. Improvements in body weight, blood
glucose levels, and total serum cholesterol were also noted.
Cairella M, Marchini G Evaluation of the action of glucomannan on metabolic parameters and on the sensation of satiation on overweight and obese patients. Clin Ter. 1995 Apr;146(4):269-74 [Article in Italian]
- Glucomannan reduces insulin surge after meals.
When administrated with meals, by blending into fluid or mixed with food, glucomannan can slow carbohydrate
absorption and inhibit insulin response after meals by up to 50%. Clinical evidence also suggests that glucomannan
promotes satiety and weight loss while improving LDL cholesterol and constipation with few side effects, if any at
all.
McCarty MF Glucomannan minimizes the postprandial insulin surge: a potential adjuvant for hepatothermic therapy. Med Hypotheses. 2002 Jun;58(6):487-90
- KGM causes 5.5 pounds of weight loss in 2 months without dieting vs. a weight gain of 1.5 pounds in those given a placebo.
Two groups of obese participants were asked to consume their regular diet. In addition, the
control group was also given 1 gram of KGM, one hour prior to each meal with 8 ounces of water, while the other group
received a placebo. At the end of the study, the control group lost an average of 5.5 pounds, while the placebo group gained 1.5 pounds.
Just as impressive, the total and LDL cholesterol levels were reduced in the KGM group. There were no adverse
effects experienced in either group.
Walsh DE, Yaghoubian V, Behforooz A Effect of glucomannan on obese patients: a clinical study. Int J Obes. 1984;8(4):289-93.
- KGM provides 10.4 pounds of weight loss in just one month.
When KGM was added to a normal-caloric diet, it caused as much weight loss in one month as those subjects consuming
a very low-calorie diet. According to the study, obese participants either consumed 2,000 calories a day and 1 gram of KGM
prior to breakfast and lunch, or consumed 1,200 calories a day and given no KGM for the duration of a month. Those
participants receiving KGM lost an average of 10.4 pounds, compared to 10.7 pounds in the extreme low-calorie group.
Herrera-Pombo JL, Sastre A, Morejon E. Efficacy of normocaloric diet in obesity treatment. International Journal of Obesity. 1996
May, 20(supplement 4):60(abstract 03-135-WP1).
- KGM causes 8 times more weight loss than a placebo -- without dieting -- and 13 times more weight
loss with dieting, over the course of one month.
Hypertensive subjects were divided into three groups consisting of those who were given 3 grams (1 gram 3 times daily)
of KGM, the second group also received KGM in addition to a low calorie diet (varying between 1,000 and 1,800 calories a day)
, while the third group received just a placebo. The KGM-only group lost 3.1 pounds, the KGM and low-calorie group lost 5.3
pounds, and the placebo group lost 0.4 pounds. Ten of the 31 participants (32%) reported a definite satiating effect. Also,
five of the subjects previously suffering from constipation reported KGM was helpful. The authors of the study concluded
"a dietary supplement, such as KGM, is therefore useful as a natural obstacle to nutrient intake in maintaining energy balance
and in the management of the overweight."
Reffo GC, et. al. Glucomannan in hypertensive outpatients: pilot clinical trial. Curr Ther Res. 1988;44:22-27.
- KGM has pronounced ability to reduce appetite, and is well tolerated over the long term for obesity.
This study examined the results of giving 4 grams of KGM (1.33 grams prior to each meal, 3 times daily) to severly obese
subjects over a three-month period, in addition to a prescribed diet. The authors of the study concluded that, "KGM
had a marked ability to satiate patients" allowing "greater adherence to the diet", and produced significant loss of
fat mass, while improving lipid levels. Additionally KGM is well-tolerated over the long term.
Vita PM, Restelli A, Caspani P, Klinger R Chronic use of glucomannan in the dietary treatment of severe obesity Minerva Med. 1992 Mar;83(3):135-9.
- Cholesterol reduced by 11 percent, fasting blood sugar by 29 percent using KGM.
Over the course of 3 months, type II diabetic patients were given KGM. Measurements of total cholesterol and fasting
blood sugar were recorded at the start and end of the study. Total cholesterol was reduced by 11%, and fasting blood sugar
levels decreased by 29%.
Doi K, Matsuura M, Kawara A, Baba S. Treatment of diabetes with glucomannan (konjac mannan). Lancet. 1979 May 5;1(8123):987-8.
- Blood glucose levels and other associated risk factors improved with KGM supplementation in Type 2 diabetics.
Eleven Type 2 diabetic subjects, who were also hyperlipidemic and hypertensive, were given KGM fiber-enriched
(konjac mannan = glucomannan) biscuits containing 0.7g/100kcal KGM in addition to traditional treatment of a low-fat
diet and medications. KGM significantly reduced serum fructosamine, the ratio of total to HDL cholesterol, and
systolic blood pressure levels. The authors concluded that KJM fiber added to conventional therapy, may improve
glycemic control, blood lipid profiles, and systolic blood pressure in high-risk Type 2 diabetic individuals, thus
further improving the effectiveness of conventional treatment protocols versus a placebo.
Vuksan V, et.al. Konjac-mannan (glucomannan) improves glycemia and other associated risk factors for coronary heart disease in type 2 diabetes.
A randomized controlled metabolic trial. Diabetes Care 1999 Jun;22(6):913-9.
*A sensible diet and regular exercise are essential for achieving your weight
loss goal.
Read and follow all label instructions before using. Consult a healthcare professional before beginning any weight loss program. When used in combination with a sensible diet and exercise program, Tetrazene can help support your weight management program. Substantial weight loss requires the product be used in conjunction with reduced caloric intake or increased physical activity. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent and disease.
|
Order Form
